Breo Ellipta

May 20, 2016May 20, 2016

Positive Data on COPD Therapy Breo Ellipta SUMMIT Study Presented by GSK

COPD, News

GlaxoSmithKline (GSK) and Innoviva recently presented positive results from two analyses of the SUMMIT trial, which investigated the efficacy and safety of Breo Ellipta (fluticasone furoate/vilanterol, or FF/VI 100/25 mcg) in patients with chronic obstructive pulmonary disease (COPD) ... Read more

May 13, 2016May 13, 2016

GlaxoSmithKline (GSK) to Present Studies on Respiratory Diseases Therapies at ATS 2016

Asthma, COPD, News

GlaxoSmithKline (GSK) recently announced that the company will present the most recent results obtained in a wide range of GSK studies, focused on their respiratory portfolio of approved medicines, at ... Read more

August 10, 2015November 6, 2015

Breo Ellipta Now Approved as Asthma Treatment for Adult Patients in Canada

Asthma, News

GlaxoSmithKline (GSK) and VIBATIV® (telavancin) developer Theravance Biopharma, have just been granted Canadian approval for Breo Ellipta, a once-a-day maintenance treatment for asthma in patients who are at least 18 ... Read more

May 5, 2015November 6, 2015

FDA Approves BREO® ELLIPTA® To Treat Adults With Asthma In The US

Asthma, News

GlaxoSmithKline and Theravance, Inc. recently announced that the FDA has approved BREO® ELLIPTA® (fluticasone furoate/vilanterol ) as a once-daily treatment of asthma for patients aged 18 and older. However, Breo ... Read more

March 25, 2015November 6, 2015

FDA Rejects GSK’s Breo Ellipta Asthma Therapy Use in Adolescents; Adult Use Approved

Asthma, News

The U.S. Food and Drug Administration (FDA) ruled against the use of GlaxoSmithKline‘s new drug combination Breo Ellipta in asthma patients between the ages of 12 and 17. However, the Pulmonary-Allergy Drugs Advisory Committee ... Read more

March 20, 2015November 6, 2015

FDA Analyzes Potential Limitations to GSK’s New Asthma Drug

Asthma, News

The U.S. Food and Drug Administration (FDA) recently produced a preliminary report regarding GlaxoSmithKline Plc‘s investigational combined therapy for the treatment of chronic breathing problems that revealed no additional safety issues. The medication, called Breo ... Read more